Early Pharmacodynamic Effects of Exenatide Once Weekly in Type 2 Diabetes Are Independent of Weight Loss: A Pooled Analysis of Patient-level Data

Clinical Therapeutics

Volumn 38, Issue 6, 2016, Pages 1464-1473

  Trautmann, Michael E ^a   Han, Jenny ^b   Ruggles, James ^c  

^a Diabetes Research Hamburg   (Germany)

^b Pharmapace Inc   (United States)

^c ASTRAZENECA   (United Kingdom)

Author keywords

diabetes mellitus; early response; exenatide; glucagon like peptide 1 receptor agonist; HbA1c; pharmacokinetics

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; EXENDIN 4; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; SULFONYLUREA; TRIACYLGLYCEROL; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; LIPID; PEPTIDE; VENOM;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG EFFECT; DRUG RESPONSE; EVALUATION STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION; AGONISTS; ANALYSIS; BLOOD PRESSURE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; META ANALYSIS; PATHOPHYSIOLOGY;

BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; LIPIDS; PEPTIDES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VENOMS; WEIGHT LOSS;

EID: 84964625776     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2016.03.039     Document Type: Article

References (31)

1. J.M. Trujillo, and W. Nuffer GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents Pharmacotherapy 34 2014 1174 1186
2. M. Diamant, L. Van Gaal, B. Guerci, and et al. Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial Lancet Diabetes Endocrinol 2 2014 464 473
3. C.H. Wysham, L.A. MacConell, D.G. Maggs, and et al. Five-year efficacy and safety data of exenatide once weekly: long-term results from the randomized, controlled DURATION-1 trial Mayo Clin Proc 90 2015 356 365
4. R.M. Bergenstal, C. Wysham, L. Macconell, and et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial Lancet 376 2010 431 439
5. D. Russell-Jones, R.M. Cuddihy, M. Hanefeld, and et al. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study Diabetes Care 35 2012 252 258
6. S.S. Grossman Pathophysiological and pharmacological rationale for the use of exenatide once weekly in patients with type 2 diabetes Adv Ther 31 2014 247 263
7. R.A. DeFronzo, T. Okerson, P. Viswanathan, and et al. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study Curr Med Res Opin 24 2008 2943 2952
8. M.B. DeYoung, L. MacConell, V. Sarin, and et al. Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes Diabetes Technol Ther 13 2011 1145 1154
9. Y.M. Cui, X.H. Guo, D.M. Zhang, and et al. Pharmacokinetics, safety, and tolerability of single- and multiple-dose exenatide once weekly in Chinese patients with type 2 diabetes mellitus J Diabetes. 5 2013 127 135
10. M. Fineman, S. Flanagan, K. Taylor, and et al. Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing Clin Pharmacokinet 50 2011 65 74
11. K. Iwamoto, R. Nasu, A. Yamamura, and et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of exenatide once weekly in Japanese patients with type 2 diabetes Endocr J 56 2009 951 962
12. Bydureon (exenatide extended-release) for injectable suspension [prescribing information] 2015 AstraZeneca Pharmaceuticals LP Wilmington, DE
13. M.S. Fineman, L.Z. Shen, K. Taylor, and et al. Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes Diabetes Metab Res Rev 20 2004 411 417
14. M. Grimm, J. Han, C. Weaver, and et al. Efficacy, safety, and tolerability of exenatide once weekly in patients with type 2 diabetes mellitus: an integrated analysis of the DURATION trials Postgrad Med 125 2013 47 57
15. E. Klein, R.R. Henry, J. Malloy, and et al. DURATION-1 extension: efficacy and tolerability of exenatide once weekly over 6 years in patients with type 2 diabetes mellitus Diabetologia 57 2014 S39-S39
16. T. Blevins, J. Pullman, J. Malloy, and et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes J Clin Endocrinol Metab 96 2011 1301 1310
17. J.B. Buse, M. Nauck, T. Forst, and et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study Lancet 381 2013 117 124
18. M. Davies, S. Heller, S. Sreenan, and et al. Once-weekly exenatide versus once- or twice-daily insulin detemir: randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas Diabetes Care 36 2013 1368 1376
19. M. Diamant, L. Van Gaal, S. Stranks, and et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial Lancet 375 2010 2234 2243
20. D.J. Drucker, J.B. Buse, K. Taylor, and et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study Lancet 372 2008 1240 1250
21. N. Inagaki, Y. Atsumi, T. Oura, and et al. Efficacy and safety profile of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with oral antidiabetes drug(s): results from a 26-week, randomized, open-label, parallel-group, multicenter, noninferiority study Clin Ther 34 2012 1892 1908.e1
22. L. Ji, Y. Onishi, C.W. Ahn, and et al. Efficacy and safety of exenatide once-weekly vs exenatide twice-daily in Asian patients with type 2 diabetes mellitus J Diabetes Investig 4 2013 53 61
23. D. Kim, L. MacConell, D. Zhuang, and et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes Diabetes Care 30 2007 1487 1493
24. P. Norwood, J.F. Liutkus, H. Haber, and et al. Safety of exenatide once weekly in patients with type 2 diabetes mellitus treated with a thiazolidinedione alone or in combination with metformin for 2 years Clin Ther 34 2012 2082 2090
25. S. Aronoff, S. Rosenblatt, S. Braithwaite, and et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group Diabetes Care 23 2000 1605 1611
26. Avandia (rosiglitazone maleate) tablets [prescribing information] 2014 GlaxoSmithKline Research Triangle Park, NC
27. M. Horowitz, V. Aroda, J. Han, and et al. Upper and/or lower GI adverse events with long- vs short-acting GLP-1 receptor agonists: incidence, co-incidence, effects on HbA1c and weight [abstract] Diabetologia 58 2015 S7
28. W.H. Polonsky Poor medication adherence in diabetes: what's the problem? J Diabetes. 7 2015 777 778
29. L. Blonde, R. Pencek, and L. MacConell Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetes Cardiovasc Diabetol 14 2015 12
30. American Diabetes Association Standards of medical care in diabetes - 2015 Diabetes Care 38 2015 S1 S94
31. P. Gaede, P. Vedel, N. Larsen, and et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes N Engl J Med 348 2003 383 393